{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T06:28:48Z","timestamp":1783232928735,"version":"3.54.6"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPF202209015771"],"award-info":[{"award-number":["SPF202209015771"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","award":["SPF202209015771"],"award-info":[{"award-number":["SPF202209015771"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["18-CE14-0018-01"],"award-info":[{"award-number":["18-CE14-0018-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-INBS-0006"],"award-info":[{"award-number":["ANR-11-INBS-0006"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Oral Sci"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Elevated fibroblast growth factor 23 (FGF23) in X-linked hypophosphatemia (XLH) results in rickets and phosphate wasting, manifesting by severe bone and dental abnormalities. Burosumab, a FGF23-neutralizing antibody, an alternative to conventional treatment (phosphorus and active vitamin D analogs), showed significant improvement in the long bone phenotype. Here, we examined whether FGF23 antibody (FGF23-mAb) also improved the dentoalveolar features associated with XLH. Four-week-old male <jats:italic>Hyp<\/jats:italic> mice were injected weekly with 4 or 16\u2009mg\u00b7kg<jats:sup>\u22121<\/jats:sup> of FGF23-mAb for 2 months and compared to wild-type (WT) and vehicle (PBS) treated <jats:italic>Hyp<\/jats:italic> mice (<jats:italic>n<\/jats:italic>\u2009=\u20093\u20137 mice). Micro-CT analyses showed that both doses of FGF23-mAb restored dentin\/cementum volume and corrected the enlarged pulp volume in <jats:italic>Hyp<\/jats:italic> mice, the higher concentration resulting in a rescue similar to WT levels. FGF23-mAb treatment also improved alveolar bone volume fraction and mineral density compared to vehicle-treated ones. Histology revealed improved mineralization of the dentoalveolar tissues, with a decreased amount of osteoid, predentin and cementoid. Better periodontal ligament attachment was also observed, evidenced by restoration of the acellular cementum. These preclinical data were consistent with the retrospective analysis of two patients with XLH showing that burosumab treatment improved oral features. Taken together, our data show that the dentoalveolar tissues are greatly improved by FGF23-mAb treatment, heralding its benefit in clinics for dental abnormalities.<\/jats:p>","DOI":"10.1038\/s41368-023-00259-8","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T03:02:03Z","timestamp":1701831723000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia"],"prefix":"10.1038","volume":"15","author":[{"given":"Elis J.","family":"Lira dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Po","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Hanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volha","family":"Zhukouskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Biosse Duplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3936","authenticated-orcid":false,"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Bardet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"key":"259_CR1","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter, T. O., Imel, E. A., Holm, I. A., Jan de Beur, S. M. & Insogna, K. L. A clinician\u2019s guide to X-linked hypophosphatemia. J. Bone Min. Res. 26, 1381\u20131388 (2011).","journal-title":"J. Bone Min. Res."},{"key":"259_CR2","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"S Hennig","year":"1995","unstructured":"Hennig, S. et al. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat. Genet. 11, 130\u2013136 (1995).","journal-title":"Nat. Genet."},{"key":"259_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1530\/EC-19-0481","volume":"9","author":"VV Zhukouskaya","year":"2020","unstructured":"Zhukouskaya, V. V. et al. Increased prevalence of overweight and obesity in children with x-linked hypophosphatemia. Endocr. Connect. 9, 144\u2013153 (2020).","journal-title":"Endocr. Connect."},{"key":"259_CR4","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1067\/mpd.2003.119","volume":"142","author":"C Chaussain-Miller","year":"2003","unstructured":"Chaussain-Miller, C. et al. Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D. J. Pediatr. 142, 324\u2013331 (2003).","journal-title":"J. Pediatr."},{"key":"259_CR5","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner, D. et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat. Rev. Nephrol. 15, 435\u2013455 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"259_CR6","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/0022034516677528","volume":"96","author":"M Biosse Duplan","year":"2017","unstructured":"Biosse Duplan, M. et al. Phosphate and vitamin D prevent periodontitis in X-Linked Hypophosphatemia. J. Dent. Res. 96, 388\u2013395 (2017).","journal-title":"J. Dent. Res."},{"key":"259_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","volume":"13","author":"C Chaussain-Miller","year":"2007","unstructured":"Chaussain-Miller, C. et al. Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment. Oral. Dis. 13, 482\u2013489 (2007).","journal-title":"Oral. Dis."},{"key":"259_CR8","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor, J. et al. Conventional therapy in adults with X-Linked hypophosphatemia: effects on enthesopathy and dental disease. J. Clin. Endocrinol. Metab. 100, 3625\u20133632 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"259_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.bone.2017.07.026","volume":"103","author":"BR Coyac","year":"2017","unstructured":"Coyac, B. R. et al. Tissue-specific mineralization defects in the periodontium of the Hyp mouse model of X-linked hypophosphatemia. Bone 103, 334\u2013346 (2017).","journal-title":"Bone"},{"key":"259_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jbmr.1767","volume":"28","author":"BL Foster","year":"2013","unstructured":"Foster, B. L. et al. Tooth root dentin mineralization defects in a mouse model of hypophosphatasia. J. Bone Min. Res. 28, 271\u2013282 (2013).","journal-title":"J. Bone Min. Res."},{"key":"259_CR11","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart, A. et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr. Connect 3, R13\u2013R30 (2014).","journal-title":"Endocr. Connect"},{"key":"259_CR12","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41574-022-00662-x","volume":"18","author":"A Trombetti","year":"2022","unstructured":"Trombetti, A. et al. Interdisciplinary management of FGF23-related phosphate wasting syndromes: a consensus statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia. Nat. Rev. Endocrinol. 18, 366\u2013384 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"259_CR13","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono, Y. et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia. J. Bone Miner. Res. 24, 1879\u20131888 (2009).","journal-title":"J. Bone Miner. Res."},{"key":"259_CR14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1359\/jbmr.080417","volume":"23","author":"Y Yamazaki","year":"2008","unstructured":"Yamazaki, Y. et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 23, 1509\u20131518 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"259_CR15","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Investig. 124, 1587\u20131597 (2014).","journal-title":"J. Clin. Investig."},{"key":"259_CR16","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter, T. O. et al. Burosumab therapy in children with X-Linked Hypophosphatemia. N. Engl. J. Med. 378, 1987\u20131998 (2018).","journal-title":"N. Engl. J. Med."},{"key":"259_CR17","doi-asserted-by":"publisher","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","volume":"107","author":"LM Ward","year":"2022","unstructured":"Ward, L. M. et al. Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 107, e3241\u2013e3253 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"259_CR18","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1210\/clinem\/dgab729","volume":"107","author":"A Linglart","year":"2022","unstructured":"Linglart, A. et al. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-Linked hypophosphatemia. J. Clin. Endocrinol. Metab. 107, 813\u2013824 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"259_CR19","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/jbmr.4641","volume":"37","author":"N Fratzl-Zelman","year":"2022","unstructured":"Fratzl-Zelman, N. et al. Bone matrix mineralization and response to burosumab in adult patients with X-Linked hypophosphatemia: results from the phase 3, single-arm international trial. J. Bone Min. Res. 37, 1665\u20131678 (2022).","journal-title":"J. Bone Min. Res."},{"key":"259_CR20","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna, K. L. et al. Burosumab improved histomorphometric measures of osteomalacia in adults with X-Linked hypophosphatemia: a phase 3, single-arm, international trial. J. Bone Min. Res. 34, 2183\u20132191 (2019).","journal-title":"J. Bone Min. Res."},{"key":"259_CR21","first-page":"e10672","volume":"6","author":"M Gadion","year":"2022","unstructured":"Gadion, M. et al. Burosumab and dental abscesses in children with X-linked hypophosphatemia. JBMR 6, e10672 (2022).","journal-title":"JBMR"},{"key":"259_CR22","doi-asserted-by":"publisher","first-page":"947814","DOI":"10.3389\/fendo.2022.947814","volume":"13","author":"R Brener","year":"2022","unstructured":"Brener, R., Zeitlin, L., Lebenthal, Y. & Brener, A. Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy. Front. Endocrinol. 13, 947814 (2022).","journal-title":"Front. Endocrinol."},{"key":"259_CR23","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1177\/00220345211011041","volume":"100","author":"EJ Lira dos Santos","year":"2021","unstructured":"Lira dos Santos, E. J. et al. Effects of active vitamin D or FGF23 antibody on Hyp mice dentoalveolar tissues. J. Dent. Res. 100, 1482\u20131491 (2021).","journal-title":"J. Dent. Res."},{"key":"259_CR24","doi-asserted-by":"publisher","first-page":"e002676","DOI":"10.1136\/rmdopen-2022-002676","volume":"9","author":"P Kamenicky","year":"2023","unstructured":"Kamenicky, P. et al. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment. RMD Open 9, e002676 (2023).","journal-title":"RMD Open"},{"key":"259_CR25","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1210\/clinem\/dgad230","volume":"108","author":"EA Imel","year":"2023","unstructured":"Imel, E. A. et al. Burosumab versus phosphate\/active vitamin D in pediatric X-Linked Hypophosphatemia: a sub-group analysis by dose level. J. Clin. Endocrinol. Metab. 108, 2990\u20132998 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"259_CR26","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bone.2015.05.007","volume":"78","author":"BL Foster","year":"2015","unstructured":"Foster, B. L. et al. Mineralization defects in cementum and craniofacial bone from loss of bone sialoprotein. Bone 78, 150\u2013164 (2015).","journal-title":"Bone"},{"key":"259_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.bone.2017.12.004","volume":"107","author":"BL Foster","year":"2018","unstructured":"Foster, B. L. et al. Osteopontin regulates dentin and alveolar bone development and mineralization. Bone 107, 196\u2013207 (2018).","journal-title":"Bone"},{"key":"259_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1177\/0022034520901719","volume":"99","author":"H Zhang","year":"2020","unstructured":"Zhang, H. et al. Dentoalveolar defects in the Hyp mouse model of X-linked hypophosphatemia. J. Dent. Res. 99, 419\u2013428 (2020).","journal-title":"J. Dent. Res."},{"key":"259_CR29","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1073\/pnas.73.12.4667","volume":"73","author":"EM Eicher","year":"1976","unstructured":"Eicher, E. M., Southard, J. L., Scriver, C. R. & Glorieux, F. H. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D resistant) rickets. Proc. Natl. Acad. Sci. USA 73, 4667\u20134671 (1976).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"259_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2020.00854","volume":"8","author":"C-A Faraji-Bell\u00e9e","year":"2020","unstructured":"Faraji-Bell\u00e9e, C.-A. et al. Development of enthesopathies and joint structural damage in a murine model of X-Linked hypophosphatemia. Front. Cell Dev. Biol. 8, 1\u201313 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"259_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/JPER.21-0119","volume":"92","author":"EJ Lira Dos Santos","year":"2021","unstructured":"Lira Dos Santos, E. J. et al. Cementocyte alterations associated with experimentally induced cellular cementum apposition in Hyp mice. J. Periodontol. 92, 116\u2013127 (2021).","journal-title":"J. Periodontol."},{"key":"259_CR32","first-page":"1","volume":"5","author":"D Clayton","year":"2021","unstructured":"Clayton, D. et al. Mineralization defects in the primary dentition associated with X\u2010Linked hypophosphatemic rickets. JBMR 5, 1\u201311 (2021).","journal-title":"JBMR"},{"key":"259_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bone.2012.01.010","volume":"50","author":"S Opsahl Vital","year":"2012","unstructured":"Opsahl Vital, S. et al. Tooth dentin defects reflect genetic disorders affecting bone mineralization. Bone 50, 989\u2013997 (2012).","journal-title":"Bone"},{"key":"259_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher, D. et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J. Inherit. Metab. Dis. 41, 865\u2013876 (2018).","journal-title":"J. Inherit. Metab. Dis."},{"key":"259_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2013-1009","volume":"35","author":"BL Foster","year":"2014","unstructured":"Foster, B. L., Nociti, F. H. & Somerman, M. J. The rachitic tooth. Endocr. Rev. 35, 1\u201334 (2014).","journal-title":"Endocr. Rev."},{"key":"259_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bone.2016.11.019","volume":"95","author":"T Boukpessi","year":"2017","unstructured":"Boukpessi, T. et al. Osteopontin and the dento-osseous pathobiology of X-linked hypophosphatemia. Bone 95, 151\u2013161 (2017).","journal-title":"Bone"},{"key":"259_CR37","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel, E. A. et al. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393, 2416\u20132427 (2019).","journal-title":"Lancet"},{"key":"259_CR38","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna, K. L. et al. A randomized, double-blind, placebo-controlled, Phase 3 trial evaluating the efficacy of Burosumab, an Anti-FGF23 antibody, in adults with X-Linked hypophosphatemia: week 24 primary analysis. J. Bone Miner. Res. 33, 1383\u20131393 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"259_CR39","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/154405910808700708","volume":"87","author":"L Ye","year":"2008","unstructured":"Ye, L., Zhang, S., Ke, H., Bonewald, L. F. & Feng, J. Q. Periodontal breakdown in the Dmp1 null mouse model of hypophosphatemic rickets. J. Dent. Res. 87, 624\u2013629 (2008).","journal-title":"J. Dent. Res."},{"key":"259_CR40","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jbmr.1766","volume":"28","author":"NMT Barros","year":"2013","unstructured":"Barros, N. M. T. et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J. Bone Min. Res. 28, 688\u2013699 (2013).","journal-title":"J. Bone Min. Res."},{"key":"259_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1007\/s00223-006-0182-4","volume":"79","author":"T Boukpessi","year":"2006","unstructured":"Boukpessi, T. et al. Dentin alteration of deciduous teeth in human hypophosphatemic rickets. Calcif. Tissue Int. 79, 294\u2013300 (2006).","journal-title":"Calcif. Tissue Int."},{"key":"259_CR42","doi-asserted-by":"crossref","first-page":"263300402210747","DOI":"10.1177\/26330040221074702","volume":"3","author":"M-H Lafage-Proust","year":"2022","unstructured":"Lafage-Proust, M.-H. What are the benefits of the anti-FGF23 antibody burosumab on the manifestations of X-linked hypophosphatemia in adults in comparison with conventional therapy? A review. Ther. Adv. Rare Dis. 3, 26330040221074704 (2022).","journal-title":"Ther. Adv. Rare Dis."},{"key":"259_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1615\/CritRevEukarGeneExpr.v22.i1.50","volume":"22","author":"PSN Rowe","year":"2012","unstructured":"Rowe, P. S. N. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit. Rev. Eukaryot. Gene Expr. 22, 61\u201386 (2012).","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"259_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/154405910208101204","volume":"81","author":"FH Nociti","year":"2002","unstructured":"Nociti, F. H. et al. Cementum: a phosphate-sensitive tissue. J. Dent. Res. 81, 817\u2013821 (2002).","journal-title":"J. Dent. Res."},{"key":"259_CR45","doi-asserted-by":"publisher","first-page":"e56749","DOI":"10.1371\/journal.pone.0056749","volume":"8","author":"B Salmon","year":"2013","unstructured":"Salmon, B. et al. MEPE-derived ASARM peptide inhibits odontogenic differentiation of dental pulp stem cells and impairs mineralization in tooth models of X-linked hypophosphatemia. PLoS One 8, e56749 (2013).","journal-title":"PLoS One"},{"key":"259_CR46","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.3074","volume":"19","author":"R Baron","year":"2013","unstructured":"Baron, R. & Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179\u2013192 (2013).","journal-title":"Nat. Med."},{"key":"259_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41368-022-00214-z","volume":"15","author":"E Guirado","year":"2023","unstructured":"Guirado, E. et al. Wnt pathway inhibitors are upregulated in XLH dental pulp cells in response to odontogenic differentiation. Int. J. Oral. Sci. 15, 13 (2023).","journal-title":"Int. J. Oral. Sci."},{"key":"259_CR48","first-page":"e10474","volume":"5","author":"MB Chavez","year":"2021","unstructured":"Chavez, M. B. et al. Guidelines for micro-computed tomography analysis of rodent dentoalveolar tissues. JBMR 5, e10474 (2021).","journal-title":"JBMR"}],"container-title":["International Journal of Oral Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00259-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00259-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T04:19:15Z","timestamp":1701836355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41368-023-00259-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["259"],"URL":"https:\/\/doi.org\/10.1038\/s41368-023-00259-8","relation":{},"ISSN":["2049-3169"],"issn-type":[{"value":"2049-3169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.N., A.H. and T.S. are industry scientists at Kyowa Kirin. A.L. reports a research grant from Kyowa Kirin, honoraria, and consulting fees from Pfizer, Novonordisk, Merck Serono and Sandoz, unrelated to this work. M.B.D. reports a research grant and honoraria from Kyowa Kirin. C.C. reports a research collaborative grant from Kyowa Kirin for URP2496 related to this work, and consulting fees from Novonordisk for URP2496 unrelated to this work. The other authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}